Hepagene hepatitis B vaccine containing all HBV surface antigens data

MDV announced results of a U.K. trial demonstrating Hepagene's effectiveness in 925 patients who were not seroprotected after at least 3 doses of

Read the full 235 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE